U.S. FDA Requests Halt To CytRx Trial Of Lou Gehrig’s Disease Drug (India)
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA has asked India's CytRx to stop its Phase II trial of a Lou Gehrig-disease drug because the company lacks the data to continue. The U.S. agency asked the company for more analysis of toxicology studies performed on animals for the arimoclomol drug aimed at treating amyotropic lateral sclerosis. CytRx said there was no data in any of the trials related to safety in humans, and the firm has asked for clarification. (Click here for more